View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
August 27, 2021

AstraZeneca’s Forxiga obtains approval in Japan for CKD treatment 

The Japanese regulator granted approval based on positive results from Phase III DAPA-CKD trial of the drug.

Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved AstraZeneca’s Forxiga (dapagliflozin) to treat chronic kidney disease (CKD) in adults with and without type-2 diabetes (T2D).

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

Forxiga is an oral, once-daily sodium-glucose cotransporter 2 (SGLT2) inhibitor with demonstrated efficacy to prevent and delay cardiorenal disease.

Earlier this year, the MHLW granted priority review status to the drug in this CKD indication and based the latest approval on positive data from the Phase III DAPA-CKD trial.

The international, multi-centre, randomised, double-blinded trial enrolled 4,304 subjects to assess the efficacy of 10mg Forxiga versus placebo in stage 2-4 CKD patients with high urinary albumin excretion, with and without T2D.

Forxiga plus standard-of-care (SoC) therapy lowered the relative risk of deterioration of renal function, the onset of end-stage kidney disease or risk of cardiovascular or renal death by 39%, the primary composite goal.

SoC treatment comprised an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker.

Forxiga also sustainably lowered the relative mortality risk from any cause by 31% versus placebo.

The drug’s safety and tolerability were in line with its already observed safety profile.

AstraZeneca BioPharmaceuticals R&D executive vice-president Mene Pangalos said: “This approval is an important step towards realising our ambition of improving outcomes for patients with chronic kidney disease.

“While new medicines like Forxiga advance the standard of care, we are also committed to the prevention and early detection of this often debilitating and life-threatening disease.”

Forxiga, also known as Farxiga, recently obtained approval in the EU and US for CKD treatment in adults with and without T2D.

The drug is intended to be used as an adjunct to diet and exercise to boost glycaemic control in adults with T2D and as an oral adjunct therapy to insulin for those with type-1 diabetes.

Ono Pharmaceutical will oversee the supply and commercialisation of Forxiga in Japan under a 2013 agreement with AstraZeneca’s Japanese subsidiary, AstraZeneca KK.

In December last year, the MHLW approved Forxiga for treating patients with chronic heart failure who are receiving standard of care in the country.

Related Companies

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology